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Chapter 2
Understanding Melanoma Progression by Gene
Expression Signatures
J. Tı´ma´r, T. Barbai, B. Gyo˝rffy, and E. Ra´so´
Abstract Malignant melanoma is the most aggressive cancer in humans and under-
standing this unique biological behavior may help to design better prognosticators
and more efficient therapies. However, malignant melanoma is a heterogenous
tumor etiologically (UV-induced or not), morphologically and genetically driven
by various oncogens (B-RAF, N-RAS, KIT) and suppressor genes (CDKN2A, p53,
PTEN). There are a significant number of studies in which prognostic gene and
protein signatures were defined based on either analysis of the primary tumors
(metastasis initiating gene set) or melanoma metastases (metastasis maintenance
gene set) affecting progression of the disease or survival of the patient. These studies
provided prognostic signatures of minimal overlap. Here we demonstrate consensus
prognostic gene and protein sets derived from primary and metastatic tumor tissues.
It is of note that although there were rare overlaps concerning the composing indi-
vidual genes in these sets, network analysis defined the common pathways driving
melanoma progression: cell proliferation, apoptosis, motility, and immune mecha-
nisms. Malignant melanoma is chemoresistant, the genetic background of which has
been unknown for a long time, but new genomic analyses have identified complex
genetic alterations responsible for this phenotype involving DNA repair genes and
oncogene signaling pathways. The advent of immunotherapy of melanoma placed
the previously defined immune signature-associated genomic prognosticators into
a new perspective, suggesting that it might also be a powerful predictor. Target
therapy of malignant melanoma has changed the standard therapy based on IFN
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and dacarbazine. Target therapy of B-RAF and KIT mutated melanomas is based on
careful selection of tumors with activating/sensitizing mutations, but has immedi-
ately raised the issue of genetic basis of constitutive or acquired resistances.
1 Introduction
Malignant melanoma represents the most aggressive human cancer, which cannot
be small enough to not threaten the life of the patient, since even the smallest
primary tumor in range of 0.5 mm in diameter has a significant potential for
distant metastatization. Unfortunately, this cancer type is also characterized by
chemo- as well as radio-resistance partially based on the immanent genetic make-
up of melanocytes designed to protect surrounding keratinocytes from UV-induced
damages. For a long time this cancer type was considered a rare tumor, but due
to changes in lifestyle over the past decades, its incidence has steadily increased
among caucasians. In addition, by reason of effective new treatments for common
cancer types, the untreatable melanoma is ranked among the leading ten causes of
cancer death in the various geographic areas of the world. Malignant melanoma
is an orphan cancer since its incidence is of no interest to the industries and it
is not a focus of basic research, hence our knowledge of this disease has only
shown moderate development during the past years. Recently, however, malignant
melanoma has entered the limelight by virtue of our increasing knowledge on its
genetics, resulting development of the first successful therapies. The aim of this
review is to summarize our knowledge on malignant melanoma and its contem-
porary histological and molecular classification, based on which a more effective
prognostication and therapy can be developed. Further, it will be demonstrated that
only an integrative approach could lead to success, where classical pathology is
combined with gene- and protein based “molecular” characterizations.
2 Melanoma Classification
2.1 Histological Classification
Malignant melanocytic tumors can histologically be classified into the following
six main categories: superficial spreading, nodular, lentigo maligna, acral, mucosal
and uveal melanomas (SSM, NM, LMM, AM, MuM and UM, respectively) [1].
However, there are also rare histological variants such as desmoplastic, nevoid,
blue nevus-associated, giant congenital nevus-associated and childhood melanomas
(Table 2.1). Based on etiology, malignant melanomas can be classified into ultravi-
olet type and non-ultraviolet type, the latter comprising ALM, MuM and UM [2]. A
novel classification is to separate two forms of UV-induced melanomas based on the
extent of UV exposure and damage: melanomas arising from skin showing signs of
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chronic sun-induced damage (CSD) and those caused by intermittent UV exposure,
reflecting critical differences in etiology rather than in actual histology [3]. Similarly
to other cancer types, it is becoming more and more evident that morphological
subtypes of a given tumor correspond to diverse etiology and molecular variants.
Accordingly, malignant melanomas can now be classified based on characteristic
predominant genetic alterations. However, despite recent major developments, clear
connection between a histological subtype and a molecular class cannot currently
be established.
2.2 Molecular Classification of Malignant Melanoma
Human solid cancers are characterized by several hundred specific genetic aber-
rations comprising mutations and copy number alterations in oncogenes and
suppressor genes. However, only a few deserve the designation as driver mutations.
In the past decade systematic genetic analyses of malignant melanomas revealed
the most frequent driver mutations, as listed in Table 2.1. In case of non-UV
melanomas a clear connection can be established between the histological variant
and molecular subtype: uveal melanomas harbor GNAQ and GNA11 mutations,
mucosal and ALM melanomas frequently contain KIT mutations [4, 5]. On the
other hand, in case of UV-induced melanomas the genetic picture is more complex
and it is difficult to connect histology directly to molecular variants. The most
frequent oncogene alteration in UV-induced melanomas is B-RAF mutation, which
is associated to nevi and melanomas derived from pre-existing nevi, both connected
to chronic sun damage of the skin (CSD). Considered the second most frequent
genetic alteration in malignant melanoma for a long time, N-RAS mutation was
not consistently connected to the UV irradiation type or any specific histological
type, though NM was suspected to have some connection. Today it is clear that
oncosuppressor gene defects are more frequent in malignant melanomas mostly
associated with the UV-induced forms, but not connected to specific histological
types: these include by rank of incidence CNKN2A, PTEN and p53. Concerning
UV-associated oncogenes, a recent study revealed that GRIN2A mutation is among
the most frequent genetic alterations in UV-induced melanomas followed by KIT,
MITF (mostly amplification), BLC2, PI3K, AKT and CDK4 [2]. In summary, it can
be stated that certain genetic alterations in malignant melanomas are connected to
UV-exposure, such as B-RAF and N-RAS, but others equally occur in UV-induced
and non-UV-induced melanomas, such as KIT, PTEN or p53.
A system biology approach to the genetics of malignant melanoma reveals
five major molecular forms of malignant melanoma (Table 2.1 and Fig. 2.1) [2].
The most frequent form is the growth factor receptor signaling one (associated
with KIT, MET and EGFR defects, 1a), where genetic defects frequently occur in
either the N-RAS-B-RAF-MAPK axis (1b) or in the PI3K-AKT-mTOR axis (1c).
The other emerging receptor signaling pathway related to malignant melanoma is
the G-protein-coupled receptor pathway (MC1R and GRIN2A), where the mutant
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Fig. 2.1 Molecular pathways
of human melanoma
receptor is GRIN2A (2a) [6], otherwise the mutant G-proteins GNAQ or GNA11
are the drivers (2b). A third signaling pathway driving a fraction of malignant
melanomas is the MITF pathway [7], where genetic alteration in both MITF and
its targets may occur. The fourth molecular category of malignant melanoma is
associated with genetic defect(s) of the cell cycle pathway regulators, CDKN2A
(4a) and CDK (4b). Finally, the fifth pathway – the genetic alterations of which char-
acterize malignant melanoma – is the “apoptotic machinery” associated melanoma,
involving p53 (5a) and BCL2 (5b) mutations. Such molecular classification is very
practical from the viewpoint of planning novel target therapies or designing clinical
trials for either existing or new drugs.
2.3 Melanoma Markers
In daily routine diagnostics malignant melanomas are defined by their characteristic
pigment production. The melanin producing apparatus is under the genetic control
of MITF regulated by the MC1R signaling pathway [7]. In malignant melanomas the
melanin producing apparatus is frequently maintained completely or fragmentally
offering an efficient tool for differential diagnosis (discriminating melanocytic
tumors from others). However, these markers are not melanoma specific since they
are expressed in all benign melanocytic lesions. MITF is responsible for stimulation
of the expression of genes, the protein products of which are members of the
melanosome including gp100/pmel17, tyrosinase and TRP1, DCT and melane-
A/MART1 (Fig. 2.2). Melanosomes are derived from ER, Golgi and lysosomal
membranes and undergo a maturation process through stage 1 to stage 4. Tyrosinase
and DCT appear in stage 2 melanosomes, while melanin pigment is present in stage
4 melanosomes. Structural proteins of the melanosomes are gp100 and MART1.
Melanocytes and melanoma cells express neurogenic protein S100, specifically
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Fig. 2.2 Melanoma and melanosomal markers. (a) Schematic representation of the maturation
of melanomosomes (MS) from stage 1–4. MITF microphthalmia transcription factor, DOPA
dihydroxyphenilalanine, DCT opachrometautomerase, TYR tyrosinase, TRP1 tyrosinase related
protein, gp100 HMB45 antigen, MART1 Melan-A, (b) S-100B immunoreactivity in skin melanoma
tissue (brown color), (c) Mart-1 immunoreactivity in skin melanoma tissue (brown color)
the “-isoform. Although it is routinely used in diagnostics, its expression is
not melanoma specific, similarly to NSE or the TA90 antigen. Among the few
melanoma specific proteins is the NG2 proteoglycan, which is sensitivity to fixation
procedures and is therefore inappropriate for routine differential diagnostics.
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There were several attempts in the past to identify melanoma specific genes,
but the majority failed since the candidates were mostly present in premalignant
lesions. LOH of apoptotic protease-activating factor-1(APAF1) gene was shown to
be a sensitive marker for malignant transformation of melanocytes [8]. Recently
a genomic approach revealed a few potential candidate marker genes, such as
p107 and RyR2 [9]. A meta-analysis of array data defined a 6-gene signature of
melanoma cells containing RAB33A, EGFR3, ADRB2, MERTK, SNF1 and ITPKB
[10]. Similarly, instead of using a single gene or set of genes, genetic approach
seems to be efficient in identifying the array of chromosomal alterations which
can discriminate malignant melanomas from dysplastic melanocytic lesions. The
resulting multiple FISH test can be applied to paraffin embedded samples.
3 Progression of Malignant Melanoma
3.1 Progression Stages and Variations
The initial phase of malignant melanoma progression is local invasion, which
involves the potential of melanoma cells to invade the covering epidermis or
underlying dermal structures. Local invasion is also characterized by formation
of dermal satellite lesions, which can further propagate in several ways as will be
outlined later. Today one of the most powerful prognostic markers for assessing the
future biological behavior of a primary melanoma is ulceration, behind which the
molecular/biological pathomechanism is still unknown (Fig. 2.3). A further strong
prognostic factor that predicts outcome of the disease is thickness of the primary
tumor, today ranging 0.5–4 mm and above [1]. As compared with any other human
solid malignancy, this is an extremely narrow size range, with a 4 mm thick lesion
having a high risk of developing distant metastasis within 10 years (Fig. 2.3) [11].
On the other hand, there is no such thing as a safe minimal melanoma, since even
at a thickness of 0.5 mm the risk of developing distant organ metastasis is quite
significant [12]. Accordingly, thickness is a rather efficient predictor of the future
biological behavior of melanomas. Curious though it may seem, there is no 100%
risk range, since even at the most advanced primary stages the metastasis risk never
reaches 100%, indicating that a significant proportion of primary tumors has no or
only limited metastatic potential (Fig. 2.4). This is the main reason why there is
continuous search for genetic or protein markers capable of reliably predicting the
individual prognosis of a given patient.
Systemic dissemination of skin melanomas can occur in the form of lymphatic or
blood vessel dissemination (Fig. 2.5). The prerequisite for this type of progression –
besides biological/genetic – is the availability of nearby local lymphatic and
blood capillaries. Unfortunately, dermal skin provides a rich network of these
capillary systems which can also be further increased by cytokines produced by
primary melanoma (VEGF-C or VEGF-A, respectively) [13]. Unlike in most other
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Fig. 2.3 Microscopic morphology of local invasion of skin melanoma. (a) Epidermal invasion,
(b) Ulceration of the epidermis by melanoma, (c) Superficial spreading melanoma, (d) Vertical
growth phase, (e) Dermal invasion (arrow)
cancer types, vascularization of malignant melanoma is provided by cooption
of preexisting blood vessels and lymphatics and not by neoangiogenesis. After
lymphatic intravasation melanoma cells can form “in transit” dermal metastases
in the lymphatics even before reaching the regional lymph nodes [14]. One of
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Fig. 2.5 Invasion and metastasis forms of skin melanoma. GI, Gastrointestinal tract
the most frequent dissemination forms of malignant melanoma is locoregional,
detectable by sentinel technology. Unfortunately, in a significant proportion of cases
disseminating melanoma cells can skip locoregional lymph nodes identifiable by
macrophage tracers and settle in so called non sentinel nodes around or beyond the
locoregional ones [1, 11, 12].
The most important systemic dissemination of malignant melanomas is vascular
dissemination (Fig. 2.5) by means of dermal venous capillaries, which can be iden-
tified either by simple microscopical analysis, or specifically by IHC identification
of blood capillaries (CD34). It is of note that satellite dermal nodules can also be a
source for the systemic dissemination of melanomas, both lymphatic and vascular,
suggesting that these features must be incorporated into future prognostication
techniques. Melanoma cells from the venous circulation will reach the lung as
the first filter organ after survival, a privilege for only a tiny proportion of tumor
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cells. However, the lung is not the most frequently involved organ in melanoma
metastatization. The simple explanation for this phenomenon is that for a significant
proportion of melanoma cells the lung tissue/environment is not an ideal milieu
for survival and proliferation [1, 12]. An alternative is that certain melanoma cells
actively search for new territories and the arterio-venous communications in the lung
provide opportunity for these cells to reach the arterial circulation and other visceral
organs. Besides the viscera, malignant melanoma of the skin is characterized by
a skin-homing potential, therefore skin metastases are frequently formed from the
arterial circulation in progressing tumors. Melanomas, however have the potential
to give metastasis to any of the visceral organs, a unique potential compared to other
solid malignancies. From the perspective of the patients, skin and lung metastases
are much less life-threatening features, unlike other metastases such as the brain,
liver, bone etc.
A strong clinicopathological predictor of melanoma aggressiveness is the pres-
ence of locoregional lymphatic metastases. However, eradication of these metas-
tases does not prevent development of distant organ metastases, suggesting that
these locoregional lymphatic metastases are not the source of the systemic disease.
On the other hand, even at high N stages (several locoregional lymph node
metastases) there is no 100% chance of having distant organ metastases, which
emphasizes the fact that there are metastasis-incompetent primary melanomas [1].
Meanwhile, according to relevant information from the literature there is continuing
debate in this respect, with data still missing to be able to specifically answer these
questions.
3.2 Progression Drivers in Preclinical Models
3.2.1 Host Factors
Clinically, skin melanoma progression is not only determined by genetic factors
residing in melanoma cells, but also equally important are the host factors, immune
mechanisms in particular. Animal models as well as clinical data suggest that
malignant melanoma is immunogenic, and efficacy of both the specific and non-
specific (innate) immunity contributes to the defense mechanism of the host in
which activated cytotoxic T cells, through the help of dendritic cells, are the major
contributors, although novel data point to the importance of the B cell-mediated
immunity as well. Oddly enough, macrophages play a controversial role in this
process [15–17].
An interesting issue is how the gender of the host affects melanoma pro-
gression. Etiological data suggest that melanoma progression is less efficient in
premenopausal women and human melanoma may express sex hormone receptors.
These observations have been confirmed in preclinical melanoma metastasis mod-
els, suggesting that efficacy of at least the liver metastatization strictly depends on
the gender of the host [18].
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3.2.2 Melanoma Metastasis Genes
The genetic factors that can fundamentally influence the invasive/organ metastatic
behaviour of melanoma cells are considered metastasis genes. Unlike in other
cancer types, expression of these “metastasis-associated” genes is much less known.
Although the expression of CD44 in melanoma is evident, the specific role of
its biological potential is highly controversial. In preclinical models, CD44 and
its v3 splice variant were shown to be important in determining motile/invasive
behavior of melanoma cells, but studies on clinical samples demonstrated highly
controversial/contradictory data [19, 20]. The TWIST transcription factor is a
prominent metastasis regulator in epithelial cancers, responsible for epithelial-
mesenchymal transitions (EMT). However, its role in melanoma is questionable due
to the equally questionable role of EMT in melanoma invasiveness [21]. On the other
hand, experimental and clinicopathological data suggest controlled downregulation
of cell adhesion molecules (i.e. E-Cadherin) and upregulation of N-cadherin during
dissemination of melanoma cells, paralleled by an intermediate filament switch
(vimentin/cytokeratin). Negative regulators of melanoma metastatization may exist,
but only few data are available on their actual role. The expression and function of
NME1/NDP kinase in melanoma are highly controversial [22]. A frequent genetic
event in experimental melanoma models is loss of the gene region coding for KISS-
1/metastin, which is the ligand of GPR45. Furthermore, the malfunction of this
ligand-receptor axis can also be due to the loss of the transcriptional co-activator,
DRIP130, in melanoma [23].
Studies on the understanding of melanoma metastatization have repeatedly
indicated the importance of integrins and their signaling pathways. The predominant
integrin expressed by animal and human melanomas is ’v“3 [24], which has a
significant role in melanoma migration and invasion, where effector kinases FAK
and ILK play prominent roles [25]. In association with these observations, it is
important that a novel melanoma metastasis gene, NEDD9, was identified in animal
models, which is a regulator of the FAK activity [26]. Importance of ’v“3 in
melanoma invasiveness is also supported by its role in regulating MMP activity,
especially that of MMP2. Similarly to other cancer types, the motile potential
of melanoma is the rate limiting factor of its metastatic potential. Studies have
indicated that the HGF-MET paracrine- and the AMF (CXC chemokine)-AMFR
autocrine axes are equally important in shaping the invasiveness and motile potential
of animal and human melanomas [27, 28].
3.2.3 Stemness
Metastatic colonization and tumorigenicity of cancers are influenced by cancer
stem cells or a subpopulation of cancer cells expressing stem cell genes [21].
Studies on melanoma stem cells have identified a subpopulation characterized by
CD20/CD133/CD271 surface markers expressing ABCB5 membrane transporter.
This subpopulation might be regulated by a morphogen NODAL (a TGF“-family
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member), resulting in multilineage differentiation potentials. NODAL acts through
its activin type receptors, forming an autocrine loop, which is also regulated by
NOTCH signaling. One of the hallmarks of stemness in melanoma is its vasculo-
genic mimicry defined by expression of endothelial genes (VE-cadherin/CD144,
EphA2, TIE-1 or even CD34), resulting in formation of vascular channels in
melanoma [29]. Another example of the plasticity of melanoma is platelet-mimicry,
which is characterized by expression of megakaryocytic genes integrin ’II“/CD41,
thrombin receptor(s), platelet 12-LOX and PAFR and producing thrombin, FBG or
PAF [30]. Both vasculogenic mimicry and platelet-mimicry have been demonstrated
to be important determinants of the metastatic potential of melanoma. Recently,
an interesting novel regulatory mechanism emerged in melanomas in association
with aggressiveness and stemness: loss of the expression of AP2’ transcription
factor by upregulation of the CREB transcription factor. These genetic alterations
lead to increased expressions of MUC18, BCL2, several pro-inflammatory- and
pro-angiogenic molecules. Activation and upregulation of CREB in melanomas
seem to be associated with the activity of PAFR and PAR1, further supporting the
importance of the platelet mimicry [31].
4 Prognostic Signatures of Malignant Melanoma
4.1 Pattern of Metastasis Initiating Genes
In the past decade genomic analyses of human melanomas have been performed,
considering the disease as a homogenous cancer entity. As previously discussed,
malignant melanoma is histologically, etiologically and genetically a heterogeneous
tumor, which is to be taken into consideration during such analyses. Another point
in question is that genetic studies on primary tumors for the determination of
prognostic signatures will identify the genes most likely to be metastasis initiators.
Although nine such studies can be found in the literature involving 139 genes
(Table 2.2) [32–40], unfortunately not all of them evaluated primary tumors,
several assessed in-transit skin metastases. Another factor of heterogeneity is that
the endpoints in these studies were also heterogeneous: progression-free survival,
overall survival, lymphatic or visceral metastasis. A previous meta-analysis of the
majority of these studies was performed, identifying a significant overlap among
these signatures. However, this overlap was due to the studies in which immune-
response signatures were defined and the vast majority of overlapping genes were
associated with host immune response [41]. We shall analyse these associations
separately in the following chapter when considering immunotherapy. Here we
focus our attention on the melanoma-gene sets.
Data collection was completed in a literature survey of gene expression data
related to aggressiveness of human MM. A search in PubMed (http://www.pubmed.
com) was conducted focusing on studies written in the English language till
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2012 using the keywords “melanoma”, “array”, “microarray”, “metastasis” and
“progression” and limiting the search to human entries. All retrieved abstracts
were reviewed and a related article search was performed on appropriate abstracts.
Articles and supplemental material were downloaded, making a gene set available
with clear descriptions of applied analytical steps and detailed results. Studies
related to single genes or arbitrarily selected genes were discarded. No threshold
was defined according to which certain genes defined as “differentially expressed”
could have shown only marginal differences. Gene symbols and Affymetrix probe
set IDs were used to identify single genes using annotation databases provided
by Affymetrix (http://www.affymetrix.com) and using the EMBL approved gene
nomenclature (http://www.genenames.org) for gene symbols. The mapping of gene
sets and the identification of overlapping genes were identified using Microsoft
Access software package. It was of no great surprise that the defined prognostic
gene sets showed very little and minimal overlap (2x) of 46 genes, where only three
genes were present in three prognostic signatures: HMMR, PTGDS and RASGRP2
(Table 2.3). Pathway analysis of the consensus prognostic gene signature using
Ingenuity software revealed top networks of DNA replication (33/46 component
genes) and cell death (30/46 component genes) built around CDKs and p53.
4.2 Pattern of Metastasis Initiating Proteins
The literature on melanoma is very rich, including studies in which a myriad of
proteins were analyzed in clinical settings to establish their prognostic role. In
one of these studies a 38 protein prognostic signature of human melanoma was
prospectively tested and validated. The study defined a 5-protein good prognosis set
containing p16/INK4A, p21/WAF1, “-catenin, FN and ATF2, the prognostic power
of which was maintained in a multivariate analysis. Recently, two independent meta-
analyses were performed resulting in two partially overlapping sets of metastasis
initiator/prognostic protein signatures (Table 2.4) [42–44]. In one study even hazard
ratio (HR) was calculated for the individual proteins composing the signature which
revealed two log differences in their prognostic value, suggesting heterogeneous
influence of the individual proteins in this list. This 43 protein signature contained
17-protein overlap with another defined melanoma protein signature of 31. Although
the individual protein of the previously validated 5-protein set could be found
in the meta-sets, it was not present in the consensus list. The overlapping genes
belonged to the regulation of proliferation of melanoma cells, to their differentiation
and genetic background. It is very interesting that the metastasis initiating gene
signature and the relevant protein signature had an overlap of two genes and their
proteins, MART1, an MITF-regulated gene and CDK2, were strongly suggestive
of their prognostic significance. A more careful analysis of the available protein
signatures revealed that BIRC5/survivin could also be found in both gene and protein
sets. Pathway analysis of this consensus protein signature using Ingenuity software
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Table 2.3 Consensus gene list of melanoma metastasis initiators [32–40]
Gene Identified by
HMMR Lugassy Winnepenninckx Conway
PTGDS Jo¨nsson Winnepenninckx Bogunovic
RASGRP2 Bogunovic Jo¨nsson Winnepenninckx
AADAT Bogunovic Jo¨nsson
ANLN Winnepenninckx Bogunovic
ARHGAP30 Jo¨nsson Bogunovic
ATAD2 Bogunovic Winnepenninckx
BIRC5 Winnepenninckx Conway
C5orf22 Bogunovic Jo¨nsson
CCL19 Winnepenninckx Bogunovic
CDK2 Jo¨nsson Bogunovic
CEBPA Lugassy Winnepenninckx
CLIC3 Jo¨nsson Winnepenninckx
CRIP1 Bogunovic Winnepenninckx
CTNNBIP1 Winnepenninckx Jo¨nsson
DLX1 Jo¨nsson Bogunovic
ECT2 Lugassy Winnepenninckx
EXO1 Bogunovic Winnepenninckx
F10 Winnepenninckx Lugassy
FGD3 Lugassy Winnepenninckx
H2AFZ Winnepenninckx Jo¨nsson
HLA-DPB1 Bogunovic Jo¨nsson
HLA-DQB1 Jo¨nsson Winnepenninckx
HOP Winnepenninckx Jo¨nsson
ICOS Jo¨nsson Bogunovic
IKZF1 Bogunovic Jo¨nsson
ITPA John Jo¨nsson
KCTD11 Lugassy Winnepenninckx
LAMA1 Bogunovic Winnepenninckx
LCK Bogunovic Jo¨nsson
LTB Bogunovic Winnepenninckx
MCM4 Winnepenninckx Bogunovic
MRPS5 Winnepenninckx John
PROM2 Jo¨nsson Winnepenninckx
PTGER2 Bogunovic Jo¨nsson
SLC45A2 Jo¨nsson Bogunovic
SPINT2 Winnepenninckx Jo¨nsson
TAPBP Winnepenninckx Jo¨nsson
TCOF1 Winnepenninckx Lugassy
TK1 Winnepenninckx Conway
TOP2A Winnepenninckx Conway
TXNIP Winnepenninckx Bogunovic
VNN2 Bogunovic Jo¨nsson
WDHD1 Winnepenninckx Bogunovic
MART1 Bitter Jo¨nsson
MCM3 Mandruzzato Winnepenninckx
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Table 2.4 Consensus metastasis initiator protein signature
Gould Rothberg et al. [42, 43] HR Consensus Schramm et al. [44]
MCAM/MUC18 16.34 Tyrosinase
Bcl-xL 8.07 ID1
Matrix metalloproteinase-2 4.5 p120
Bcl-6 3.98 E-cadherin
Bcl-2 3.42 N-cadherin
pRb 3.4 pRb pRb
p27/KIP1 3.08 Osteonectin
RING1B 2.89 RhoC
Cyclin E 2.89 MMP1
Ki-67 2.66 MMP9
Double minute-2 2.49 DM-2 DM-2
gp100 2.29 ILK
PCNA 2.27 PCNA PCNA
p53 2.19 LDH5
CXCR4 2.07 Glypican-3
p21/WAF1 1.98 HES-1
Tissue plasminogen activator 1.9
Cyclin-dependent kinase-6 1.86
Mum-1/IRF4 1.64
Survivin 1.62
MelanA/MART-1 1.57 MART1 MART1
PH1 1.5 PH1 PH1
MHC class II (HLA-DR, -DP, -DQ) 1.47
Mel-18 1.31 MEL-18 MEL-18
Cyclin D3 1.14 CCND3 CCND3
Cyclin D1 1.07 CCND1 CCND1
Skp2 1.06 SKP2 SKP2
p16/INK4a 0.29
Cyclin-dependent kinase-2 0.38 CDK2 CDK2
P-cadherin 0.44 P-cadherin P-cadherin
CD44 (variant 3) 0.53 CD44 CD44
STAT-1 0.64 STAT-1 STAT-1
c-Kit 0.65 c-KIT c-KIT
Protein kinase C-“ 0.7 PKCb PKCb
Cyclin B1 0.73
Caveolin 0.73 Caveolin Caveolin
Topoisomerase II 0.78
Cyclin-dependent kinase-1 0.83 CDK1 CDK1
Ku70 0.87
Ku80 0.87
nm23 0.87
Cyclin A 0.89
BMI-1 0.92
HR hazard ratio of death
p < 0.05
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Fig. 2.6 Integrated network analysis of metastasis initiating consensus gene- and protein
signatures (Tables 2.3 and 2.4). (a) Network 1. was built around cyclins and p53
revealed again p53/cell death- (23/43) and cell cycle networks (22/43), as major
components of this signature.
Integrated network analysis of consensus metastasis initiating genes and proteins
resulted in two major networks (Fig. 2.6), one built around cyclins and p53
(Fig. 2.6a) as well as a KIT-BCL2-RB-CCND1 axis (Fig. 2.6b) from 30% of the
involved genes and proteins. Accordingly it can be concluded that the metastasis
initiating genes and proteins in the consensus signatures were barely overlapped,
the network analysis revealed that cell cycle regulation and cell death networks
involving p53 and cyclins were common components of the two signatures. These
data support the notion that gene defects of p53 and cyclins are important genetic
factors determining metastatic potential of malignant melanoma.
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Fig. 2.6 (continued) (b) Network 2. was based on a KIT-BCL2-RB1-CCND1 axis. Analysis was
performed by Ingenuity software
4.3 Pattern of Metastasis Maintenance Genes
Five genomic studies were also found in the literature, which defined prognostic
signature by comparing melanoma metastasis to the primary tumors (Table 2.5)
[45–49]. This approach can define the so called metastasis maintenance genes
which are responsible for the development of the metastatic tissue. Since almost
all studies compared lymphatic metastases to the primary, it can be concluded that
such a gene set most probably defines the lymph node metastasis-maintenance
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Table 2.5 Metastasis maintenance gene signatures of human melanoma (Modified and updated
from Tı´ma´r et al. [50])
Becker et al. [45] Haqq et al. [46] Jaeger et al. [47] Riker et al. [48] Jewel et al. [49]
Upregulated Upregulated Upregulated Upregulated Upregulated
Syntaxin REH AQP3 MAGEA1/2 CSF3
RNPL3 DSC1 MMP14 ERBB4
UBE21 CSAG2 FGF3
eIF2g PLG
PLA2G2A
Downregulated Downregulated Downregulated Downregulated MOS
TRP2 IGFBP1 LGALS7 SPRR1A/B FGF8
MDA-7 HLA-DQ TACSTD2 KRT6/15/16/17 TFF1
Desmin HLA-B1/2 KRT10/14 AQP3 FGF6
S100A2 SFN CD24 FGF15
RBP1 FGFBP1 FLG
GPD1 IVL
LUM KLK7 Downregulated
HPS1 LGALS7 MMP2
TMP21 LOR ETV6
COL3A1 RAB25 PDGFRB
COL5A3 SFN KIT
ZNFN1A5 ICEBERG FYN
ALOX5 HAS3 EMS1
KITLG TP73L PRCC
PDGFRA RORA CREBBP
FBLN2 POU2F3 MX1
TMPRSS4 GAS7
gene set. Similar to metastasis-initiating genes, these studies barely overlap with
a few genes in the signature: AQP3, LGALS7, SFN and PDGFR. A thorough meta-
analysis of the publicly available data sets was performed using robust bioinformatic
technology. The analysis identified 350 genes with a central core of 17 genes present
in three signatures (Table 2.6) [50]. This signature contained several well established
prognostic genes of malignant melanoma including osteopontin, BCL2, WNT5a
and EGFR. Pathway analysis of this signature by Ingenuity software indicated that
significant pathways equally involved were cell cycle, cell death as well as cell
movement. Interestingly, network analysis provided a single network from more
than 80% of the signature built around p53, PPARG and SPP1/OPN.
4.4 Pattern of Metastasis Maintenance Proteins
A recent meta-analysis was performed to define the metastasis maintenance protein
set of malignant melanoma with prognostic potential (Table 2.7) [51]. This analysis
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Table 2.6 Consensus matestasis maintenance gene signature of Tı´ma´r
et al. [50]
Symbol Gene description
CKS2 CDC28 protein kinase regulatory subunit 2
DSC3 Desmocollin 3
EGFR Epidermal growth factor receptor
CDC6 Cell division cycle 6 homolog
CTNNBIP1 Catenin, beta interacting protein 1
H2AFV H2A histone family, member V
CXCL14 Chemokine (C-X-C motif) ligand 14
CSAG2 CSAG family, member 2///CSAG family, member 3B
WNT5A Wingless-type MMTV integration site family, member 5A
SPP1 Secreted phosphoprotein 1
CLIC3 Chloride intracellular channel 3
PLP1 Proteolipid protein 1
AP1S2 Adaptor-related protein complex 1, sigma 2 subunit
BCL2A1 BCL2-related protein A1
AHNAK AHNAK nucleoprotein
S100A2 S100 calcium binding protein A2
KRT15 Keratin 15
found a 28-protein signature containing several host factor derived growth factors
and cytokines and only a few clearly melanoma-specific proteins, such as RAR’,
MAGE1/4, IGFBP4. Pathway analysis revealed that these proteins belonged to cell
proliferation, cell death and cell movement pathways as well as to a unique IFN-
signaling pathway. Network analysis further supported this finding revealing that
almost half of the proteins of this signature were members of an IFN-signaling
network.
An integrated network analysis was then performed on the metastasis mainte-
nance gene and protein signatures. A single network was composed from 50% of
the composite genes and proteins built around major nodes as IFN- and integrin
signaling (Fig. 2.7) further supported the notion that melanoma progression, at least
from established metastatic foci, is fundamentally influenced by immunological
factors involving IFN signaling.
4.5 Consensus Prognostic Signature
From a practical point of view, a prognostic signature of a cancer can be derived
from either the primary tumor or the metastasis, depending on the relative con-
tribution of metastasis-initiating or maintenance genes or proteins. Our analysis
identified two prognostic gene sets from these two gene pools which barely overlap
(CTNNBIP1, CLIC3 and H2AFZ), suggesting that both types of genes are critical
in metastasis formation of malignant melanoma, therefore prognostic signatures
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Table 2.7 Consensus
metastasis maintenance
protein signature derived
from Gould Rothberg and
Rimm [51]
Securin/pituitary tumor transforming gene
PRSS11/HTRA1
Transforming growth factor-“ (all isoforms)
Insulin-like growth factor binding protein-4
Interferon-inducible protein kinase
Platelet-derived growth factor receptor-“
Rap1-GAP
Retinoic acid receptor-’
Bak
Bok
Myeloid leukemia-1 (Mcl-1)
Ezrin
Galectin-1
Heparanase-1
Integrin-’4
Integrin-’5
Monocyte chemoattractant protein-1
Ferritin light chain
Calnexin
Interferon regulatory factor-1
Interferon regulatory factor-2
Interleukin-1’
Interleukin-24
MAGE-1
MAGE-4
Neutral endopeptidase/CD10
Tumor necrosis factor-“/lymphotoxin-A
’-Melanocyte-stimulating hormone
can be derived from both of them. A similar conclusion could be drawn from
the protein based prognostic signatures, where no overlap was found between the
metastasis initiating and maintenance proteins. However, comparison between the
gene- and protein sets identified BCL2 and OPN in the metastasis initiating protein
sets to be present in the metastasis maintenance gene set as well (although in dif-
fering degrees), supporting their prognostic significance and biological importance.
A pathway analysis by Ingenuity software was used to compare the two consensus
prognostic gene sets obtained from primary tumors or metastatic tissues (presented
on Tables 2.3 and 2.6). It was possible to build two networks from 50% of the
genes involved, where the major network contained 30% of the genes (Fig. 2.8)
involving cyclins and CDKs, supporting the notion that cell cycle regulation is a
major factor in melanoma metastasis. A similar informatic analysis performed on
the two consensus protein signatures also resulted in two networks built from 50%
of the protein components. Interestingly, the major network of the protein signatures
corresponded to the cell cycle regulation network as well, further supporting the data
obtained from the gene signature analysis.
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Fig. 2.7 Integrated network analysis of consensus metastasis maintenance gene- and protein
signatures (Tables 2.6 and 2.7). The network contains 50% of composite elements and is built
around IFN- and integrin signaling pathways. Analysis was performed by Ingenuity software
Experimental/preclinical studies provided ample data on the metastasis genes of
human melanomas. It can be interpreted as a critical comment that almost none of
the genes and proteins analyzed above were found in the signatures. The reasons
for such an intriguing discrepancy are that preclinical data have not been further
tested systematically on human materials, and/or such data are too specific for the
melanoma models used.
In summary, there are interesting attempts in the literature to find relatively small
gene- or protein signatures of malignant melanoma, which could be used to improve
prognostication of the disease. However, selection of such genes/proteins must be
based on careful unbiased evaluation and prospective validation. As an additional
difficulty, any further study must be based on the molecular subclassification of the
once considered “homogeneous” malignant melanoma and the signatures must be
subclassified accordingly. Otherwise a virtually blind rally will be continued in the
literature where subsequent studies will produce never-repeatable results.
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Fig. 2.8 Integrated network analysis of consensus prognostic melanoma gene signatures
(Tables 2.3 and 2.6). Network 1. was built from 30% of components around cell cycle regulators.
Analysis was performed by Ingenuity software
5 Genetic Prediction of Therapeutic Sensitivity
5.1 Chemotherapy
Malignant melanoma is considered a chemotherapy resistant cancer, the exact
genetic background of which is still unknown. The typical apoptotic resistance of
melanocytes is inherited to transformed melanocytes where defects in apoptotic
genes characterize only a subset of tumors which carry p53 or BCL2 mutations.
Melanoma stem cells represent a small subpopulation, which express the ABCB5
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multidrug transporter., Chemotherapy of malignant melanoma relies almost exclu-
sively on dacarbazine/DTIC treatment, which is the only registered chemotherapy
since decades in this cancer type, characterized by a very low response rate (below
10%) and even lower efficacy. Sensitivity of melanoma and other cancer types to
dacarbazine is considered to be in correlation with expression and activity of the
DNA repair protein MGMT [52]. Novel studies indicate that increased constitutive
expression of MGMT is correlated with poor response to dacarbazine, or its novel
variant temozolomide [53]. On the other hand, these studies also revealed that
besides MGMT, p16/INK4A levels might also affect responsiveness to DTIC/TMZ.
In an elegant study it was proved that overexpression of p16 and the mutant B-RAF
status are responsible for the melphalan and actinomycin-D resistance of human
melanomas [54].
The most complex genomic analysis of the chemoresistance of malignant
melanoma patients (472 tumors) was performed recently [55], defining RAD51 and
TOPO2A as significant predictors of chemotherapy/DTIC response. However, it has
to be mentioned that the overexpression of these genes in resistant tumors was in the
range of 1.22 and 1.12, respectively, which raises the issue of how to detect such a
small alteration of gene expression reliably in a clinical situation. In a small subset of
these patients a comprehensive analysis of chemosensitivity genes was performed,
which discovered a much more profound alteration of expressions in critical genes
including several DNA repair genes with overexpression in a range of 2–4 fold
(MSH6/2, XRCC1/5, ERCC1, MGMT). These repair genes included a wide variety
of homologue- mismatch- and nucleotide excision repair genes. Furthermore, it was
interesting that the AKT signaling pathway (PI3K and mTOR), Ki67, TS, HSP90
and SOD1 were among the most over- or underexpressed genes in chemoresistant
tumors. This is the first comprehensive picture of DNA repair associated genes in
malignant melanoma, which may shed light on the previously mentioned resistance
to various chemotherapies.
5.2 Immunotherapy
One of the most critical host derived prognostic factors influencing progression of
malignant melanoma is activity of the immune system. This conclusion is based
on two types of approaches, direct detection and evaluation of TIL composition in
melanoma and gene expression signatures (Table 2.8). Three independent genomic
analyses performed on human melanomas revealed partially overlapping immune-
signatures representing genes associated with T cells and their antitumoral activity
[33, 37, 38]. Survival analysis indicated that patients with tumors characterized
by immune-signature have significantly better survival rates [38]. On the other
hand, another study found that in a significant proportion of melanoma patients
(30%) peripheral T cells are defective in signaling, suggesting a tumor-induced
immunosuppressive effect [17]. Taken together, one can divide malignant melanoma
patients into three categories based on the activity of the antitumoral immune
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Table 2.8 Comparison of good prognosis immune-signatures of human melanoma
Mandruzzato et al. [33] Bogunovic et al. [37] Jo¨nsson et al. [38] Jo¨nsson et al. [38]
Good prognosis Good prognosis
Good prognosis
(10-gene set)
Good prognosis
(30-gene set)
HLA-DR CXCL13 ME1 ADA
HLA-B4 TLR10 NR5A2 BCAR1
TRA CCL19 CCL16 C3AR1
LTB CD3D CLEC4GP1 CD19
TNFAIP3 FCAMR LYVE1 CD3E
IL-4R CCR7 F13A1 CD79A
IGLL1 LCK CCL13 FYN
CD1D CD69 CCL23 IKBKG
CD2 IL2RG CD209 KLRK1
ITK TNFRSF17 FOLR2 LAT2
SOD2 CD2 LAX2
DAF CD27 LCK
GZMK CD48 LYN
CD53 ZAP70 MALT1
CST1 LTB MAP3K7
JUNB CD79A MAPK1
NFKBIZ IRF8 MICA
LYZ CSF2RB MICB
UBD GBP2 NFAM1
TMSB4X IRF1 PLCG2
DUSP5 NLRC3 PSEN1, 2
CLEC4G PTPRC
RIPK2
SKAP1
SPG21
SYK
TRAF6
UBE2N
mechanisms (active, passive and defective), which could be the basis of tailored
immunotherapy of malignant melanomas.
Up until now, the most effective therapy for malignant melanomas was cy-
tokine therapy using IL-2 or IFN’2. Meta-analyses indicated that both higher
and lower doses of IFN have the most beneficial effects in case of a small,
but significant proportion (10–20%) of melanoma patients [56]. Studies on the
possible predictive factors for IFN therapy revealed that the STAT1/STAT3 ratio
might be a prognosticator in both melanomas and lymphocytes (56). Unfortunately,
the previously mentioned antitumoral immune-activity stratified evaluation of IFN
sensitivity has not yet been performed in case of melanoma patients. In this context,
it is interesting that patients with ulcerated melanoma (a high risk group of poor
outcome) benefit the most from IFN therapies. In the past decade there were
attempts to define the IFN-resistance of cancers including malignant melanoma
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Table 2.9 Interferone modulated gene signature of human melanoma
(Krepler et al. [58])
Upregulated Downregulated
IRE-negative genes (fold difference >6) b-cam YKT6
AchR-E PRL-1
LamR PDK1
RPP1 CL-100
SB-IIAgA STAM2
GPCRHG38 AML1b
Ig-LCh GalK
JM1 HSP70B
HLA-III INGL1
ALP VEGF
p38PI3K IGFRS1
MGSA
TGFb
IRE-positive genes (fold difference >2) RIG-E
IF9-27
MxB
p27/KIP1
IRE interferon responsive element in promoter
by expression profiling [57]. Unfortunately, these studies were mostly based on in
vitro obtained signatures and were not evaluated in melanoma patients. The IFN
sensitivity/resistance signature contained IFN-regulated transcription factors, HLA
antigens and several IRE-containing and IRE-negative genes (Table 2.9) [58]. Based
on these studies an IFN response gene array was produced (www.superarray.com).
It is of note that the majority of genes associated with IFN sensitivity were IRE-
negative, but mostly disregulated genes. Also of note is that among the upregulated
genes PI3K could be found, whereas HSP70, VEGF and TGF“ were present among
the downregulated genes. Unfortunately, neither this, nor a similar signature was
used in recent clinical trials in which IFN-efficacy was determined in malignant
melanomas.
Most recently, the first immunotherapy of cancers was registered in malignant
melanomas, which can extend survival in about 10% of the patients. This target
therapy uses anti-CTLA4 antibody, Ipilimumab, to suspend the immunosuppressive
effect of T cells. Initially, this antibody therapy was found to be active in HLA-
A0201 positive patients [59], but in a subsequent trial this type of selection
was not used [60]. Ipilimumab target Treg cells can be found in primary and
metastatic melanoma lesions. However, the prognostic role of Treg density in skin
melanoma was not demonstrated convincingly. It is of note that the previously
demonstrated immune-gene signatures do not contain CTLA4 or FOXP3, markers
of Tregs. Unfortunately, in Ipilimumab trials no analyses were performed in order
to demonstrate association with Treg cell density or CTLA4 expression levels.
Another anti-CTLA4 antibody, Tremelimumab, was also used in trials related to
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advanced melanoma cases, in which decreased Treg cell density was demonstrated
in treated tumor samples [17]. Meanwhile the question is still valid, how can
melanoma patients be stratified for more effective anti-CTLA4 therapies? This is
an important question, since one of the most frequent side effects of anti-CTLA4
therapy is induction of severe autoimmune responses accordingly, a more tailored
administration of this treatment regime is necessary.
5.3 Target Therapy
In Part 1 we showed that malignant melanoma can be classified based on predom-
inating gene defects indicating a genetically heterogeneous tumor type. The most
frequently mutated gene in malignant melanoma is B-RAF, which characterizes the
majority of tumors. Another frequently mutated oncogene in melanoma is c-KIT,
which unlike B-RAF, is present in both UV-induced and non-UV induced (rare)
variants. These two mutations recently became successful targets for molecular
therapy, fundamentally changing the management of malignant melanoma patients.
Vemurafenib is a highly selective inhibitor of mutated B-RAF and clinical trials
have been highly successful in treating V600E mutated melanoma patients in
monotherapy, demonstrating almost 50% response rates and significant extension
of survival [61, 62]. The success of this target therapy is based on the selection of
patients for V600E-mutated B-RAF expressing tumors as positive predictor of effi-
cacy. Even in this situation the extent of antitumoral effect of Vemurafenib is limited
in the majority of patients, with an occurrence of relapse sooner or later during the
treatment. Therefore it is of high importance to define negative prognosticators or
genetic constellations of constitutive resistance to B-RAF inhibitions. Till now, there
have been no data on the constitutive mechanisms of resistance to Vemurafenib,
though the response rate indicates that such mechanisms are frequently present in
malignant melanomas. A recent pilot study suggested that PTEN-loss could be one
of those genetic determinants, which are present in a significant proportion of skin
melanomas. Genetic analysis of tumors of Vemurafenib-relapsed patients indicated
several acquired resistance mechanisms. These include emergence of N-RAS
mutated tumor cell population [63], development of MEK1C121S mutation [64] and
overexpression of signaling pathway members B-RAF, C-RAF, and MAP3K8/COT
[65]. It was also noted that overexpression of previously overseen growth factor
pathways of melanoma could lead to Vemurafenib resistance involving HER2, AXL
and PDGFR“ receptors. It is of note that certain prognostic signatures of melanoma
contain AXL and/or PDGFR, suggesting that these resistance mechanisms could
be constitutive rather than acquired in a proportion of malignant melanomas. Stud-
ies revealed other frequently acquired genetic alterations in Vemurafenib treated
melanomas affecting ERBB4, FLT1, PTPRD, RET, TERT and RUNX1T1, associa-
tion of which with mutant B-RAF inhibition failure is under investigation [64].
Target therapy of KIT-mutated human melanoma was also tested in two clinical
trials using KIT-inhibitor TKI, Gleevec. Patient selection was based on detection
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of KIT mutations. In the two trials the overall response rate was in the range of
16–23% [66, 67]. The most common mutations were similar to those found in GIST
involving exons 9, 11, 13, 17 and 18. The copy number of KIT did not prove to
be affecting Gleevec response in melanoma. On the other hand, exon 11 and 13
mutations seemed to be sensitizing KIT mutations in melanoma as compared with
exons 9, 17 or 18. Genetic analysis also raised the issue of relative proportion of
mutant KIT to wt allele, since a ratio higher than 1 was shown to be a significant
Gleevec-sensitizing genetic factor. These phase-II trials did not provide a more
comprehensive insight into the genetic factors affecting KIT-inhibitor therapy of
malignant melanoma, but indicated several melanoma-specific factors which are
different from KIT mutated GIST. Further molecular analyses are urgently needed
to resolve these issues.
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